PSAB
MCID: PLY068
MIFTS: 43

Polysubstance Abuse (PSAB)

Categories: Genetic diseases

Aliases & Classifications for Polysubstance Abuse

MalaCards integrated aliases for Polysubstance Abuse:

Name: Polysubstance Abuse 56 54 71
Polysubstance Abuse, Susceptibility to 56 29 39
Drug Addiction 56 54
Drug Addiction, Susceptibility to 56
Drug Dependence 71
Psab 56

Classifications:



External Ids:

OMIM 56 606581
UMLS 71 C0747752 C1510472

Summaries for Polysubstance Abuse

MalaCards based summary : Polysubstance Abuse, also known as polysubstance abuse, susceptibility to, is related to drug dependence and pain agnosia. An important gene associated with Polysubstance Abuse is FAAH (Fatty Acid Amide Hydrolase), and among its related pathways/superpathways are Circadian entrainment and Monoamine GPCRs. The drugs Cisatracurium and Sufentanil have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and nervous system

More information from OMIM: 606581

Related Diseases for Polysubstance Abuse

Diseases related to Polysubstance Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 425)
# Related Disease Score Top Affiliating Genes
1 drug dependence 30.4 DRD3 DRD2 CNR1
2 pain agnosia 30.1 FAAH CNR1
3 withdrawal disorder 30.1 FAAH DRD2 CNR1
4 cocaine abuse 30.0 DRD3 DRD2
5 opioid abuse 30.0 DRD3 DRD2
6 sexual disorder 29.9 DRD3 DRD2
7 bruxism 29.7 DRD3 DRD2
8 traumatic brain injury 29.6 DRD2 COMT
9 brain injury 29.6 DRD2 COMT
10 opioid addiction 29.6 DRD2 COMT
11 alcohol use disorder 29.6 DRD3 DRD2 COMT
12 kleptomania 29.5 DRD3 DRD2
13 substance abuse 29.5 DRD3 DRD2 COMT CNR1
14 trichotillomania 29.5 DRD3 DRD2
15 heroin dependence 29.5 DRD2 COMT
16 opiate dependence 29.4 DRD3 DRD2 CNR1
17 amnestic disorder 29.4 DRD2 CNR1
18 borderline personality disorder 29.3 DRD2 COMT
19 pathological gambling 29.2 DRD3 DRD2 COMT
20 phobic disorder 29.1 DRD2 COMT
21 alexithymia 29.1 DRD2 COMT
22 antisocial personality disorder 29.1 DRD2 COMT
23 personality disorder 29.1 DRD3 DRD2 COMT
24 movement disease 29.1 DRD3 DRD2
25 social phobia 29.1 DRD2 COMT
26 mood disorder 29.1 DRD3 DRD2 COMT
27 mental depression 29.0 DRD3 DRD2 COMT
28 irritable bowel syndrome 29.0 COMT CNR1
29 obsessive-compulsive disorder 29.0 DRD3 DRD2 COMT
30 attention deficit-hyperactivity disorder 28.8 DRD3 DRD2 COMT
31 tobacco addiction 28.8 DRD3 DRD2 COMT CNR1
32 psychotic disorder 28.7 DRD3 DRD2 COMT CNR1
33 cocaine dependence 28.7 DRD3 DRD2 COMT CNR1
34 impulse control disorder 28.6 DRD3 DRD2 COMT
35 bulimia nervosa 28.6 DRD2 COMT CNR1
36 post-traumatic stress disorder 28.6 FAAH DRD2 COMT CNR1
37 body mass index quantitative trait locus 11 28.6 FAAH DRD2 COMT CNR1
38 substance dependence 28.5 DRD3 DRD2 COMT CNR1
39 disease of mental health 28.5 DRD3 DRD2 COMT CNR1
40 major depressive disorder 28.4 DRD3 DRD2 COMT CNR1
41 alcohol dependence 28.4 FAAH DRD3 DRD2 COMT CNR1
42 bipolar disorder 28.3 DRD3 DRD2 COMT CNR1
43 autism 28.3 DRD3 DRD2 COMT CNR1
44 autism spectrum disorder 28.3 DRD3 DRD2 COMT CNR1
45 dystonia 28.3 DRD3 DRD2 COMT CNR1
46 eating disorder 28.2 FAAH DRD3 DRD2 COMT CNR1
47 cannabis abuse 28.2 FAAH DRD2 COMT CNR1
48 gilles de la tourette syndrome 28.1 DRD3 DRD2 COMT CNR1
49 anxiety 28.0 FAAH DRD3 DRD2 COMT CNR1
50 migraine with or without aura 1 28.0 FAAH DRD3 DRD2 COMT CNR1

Graphical network of the top 20 diseases related to Polysubstance Abuse:



Diseases related to Polysubstance Abuse

Symptoms & Phenotypes for Polysubstance Abuse

Clinical features from OMIM:

606581

MGI Mouse Phenotypes related to Polysubstance Abuse:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.35 CNR1 COMT DRD2 DRD3 FAAH
2 nervous system MP:0003631 9.02 CNR1 COMT DRD2 DRD3 FAAH

Drugs & Therapeutics for Polysubstance Abuse

Drugs for Polysubstance Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 282)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisatracurium Approved Phase 4 96946-41-7
2
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
3
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
4
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
5
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
6
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
7
Didanosine Approved Phase 4 69655-05-6 50599
8
Zidovudine Approved Phase 4 30516-87-1 35370
9
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
10
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
11
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
12
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
13
Methadone Approved Phase 4 76-99-3 4095
14
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
15 Dexketoprofen trometamol Phase 4
16 Neuromuscular Blocking Agents Phase 4
17 Antacids Phase 4
18 Proton Pump Inhibitors Phase 4
19 Anti-Ulcer Agents Phase 4
20 Pharmaceutical Solutions Phase 4
21 Antipyretics Phase 4
22 Respiratory System Agents Phase 4
23 Antitussive Agents Phase 4
24 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
25 Anti-Infective Agents Phase 4
26 Antimetabolites Phase 4
27 Serotonin Receptor Agonists Phase 4
28 Dopamine Antagonists Phase 4
29 Anti-Retroviral Agents Phase 4
30 Serotonin 5-HT1 Receptor Agonists Phase 4
31 Antiparasitic Agents Phase 4
32 Antiprotozoal Agents Phase 4
33 Cytochrome P-450 Enzyme Inhibitors Phase 4
34 Reverse Transcriptase Inhibitors Phase 4
35 Anti-HIV Agents Phase 4
36 Antiviral Agents Phase 4
37 Immunosuppressive Agents Phase 4
38 Immunologic Factors Phase 4
39 Calcineurin Inhibitors Phase 4
40 Benzonidazole Phase 4
41 Anti-Inflammatory Agents Phase 4
42 Excitatory Amino Acid Antagonists Phase 4
43 Anesthetics Phase 4
44 Anti-Arrhythmia Agents Phase 4
45 Anesthetics, General Phase 4
46 Anesthetics, Intravenous Phase 4
47 Anesthetics, Dissociative Phase 4
48 Anesthetics, Local Phase 4
49 Sodium Channel Blockers Phase 4
50 Diuretics, Potassium Sparing Phase 4

Interventional clinical trials:

(show top 50) (show all 288)
# Name Status NCT ID Phase Drugs
1 An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings Unknown status NCT00124358 Phase 4 Buprenorphine
2 Intravenous Paracetamol Versus Intravenous Dexketoprofen in Patients Presented With Dysmenorrhea in Emergency Department Unknown status NCT02373514 Phase 4 Paracetamol;Dexketoprofen
3 The Efficacy and Optimal Dose of Sufentanil in Patient Controlled Analgesia After Moderate Surgery Unknown status NCT02503826 Phase 4 Sufentanil;Sufentanil;Sufentanil;Midazolam;propofol;cisatracurium
4 Clinical Trial: Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and GERD-related Sleep Disturbances in Patients With Erosive GERD Unknown status NCT02277886 Phase 4 sodium alginate;esomeprazole
5 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
6 On-Site Addiction Treatment With Buprenorphine in HIV Clinical Care Settings Completed NCT00317460 Phase 4
7 Effects of Intranasal Oxytocin on Cigarette Smoking Completed NCT02595749 Phase 4 Oxytocin;Placebo
8 A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4 Methadone;Buprenorphine/naloxone
9 Target-controlled Infusion vs Patient-controlled Sedation With Propofol in ERCP. A Randomized Prospective Clinical Trial Completed NCT01072435 Phase 4
10 Efficacy and Safety of Intravenous Tramadol Versus Intravenous Paracetamol for Relief of Acute Pain of Primary Dysmenorrhea: A Randomized Controlled Trial Completed NCT03509740 Phase 4 tramadol;paracetamol
11 Drug Contextual Conditioning With in Humans: Causes and Consequences Completed NCT03075501 Phase 4 Stimulant or sedative;Placebo
12 Dexmedetomidine vs Placebo in ERCP Sedation.A Randomized Pilot Study Completed NCT01070680 Phase 4 Precedex;sodium chlorid 0,9%
13 Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth Completed NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
14 Effect of Dexmedetomidine on Mortality, Duration of Mechanical Ventilation and Multi-organ Function in Sepsis Patients Under Lighter Sedation by Randomized Control Trial Completed NCT01760967 Phase 4 Dexmedetomidine
15 Aripiprazole (Abilify) Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4 Aripiprazole
16 A Multicenter, Randomized, Open Label, Clinical Trial Comparing a QD Regimen of Didanosine, Lamivudine and Efavirenz With a Standard BID Regimen of Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of Human Immunodeficiency Virus Infection (GESIDA 39/03) Completed NCT00256828 Phase 4 didanosine + lamivudine + efavirenz
17 Randomized Therapeutic Study of a Treatment by Tacrolimus Adapted or Not According to the Genotype of the Cytochrome P450 3A5 After Renal Transplantation Completed NCT00552201 Phase 4 Tacrolimus
18 Transcranial Direct Current Stimulation for Treatment of Childhood Pharmacoresistant Lennox-Gastaut Syndrome, A Pilot Study Completed NCT02731300 Phase 4
19 Optimization of Sampling Procedure for PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Treated With Benznidazole in Aiquile, Bolivia Completed NCT01678599 Phase 4 Benznidazole
20 Intravenous Lidocaine for Perioperative and Postoperative Analgesia Recruiting NCT03921567 Phase 4 Lidocaine Hydrochloride;Lidocaine Hydrochloride and Ketamine;Placebo
21 Neuroplasticity Following Theta-Burst Stimulation in Cocaine Use Disorder Recruiting NCT02927236 Phase 4
22 A Prospective, Sixteen-Week, Double-Blind, Placebo-Controlled, Trial of Seroquel in Combination With Treatment as Usual in Patients With GAD and Remitted Comorbid Opiate Dependence Terminated NCT00668265 Phase 4 Quetiapine
23 Oxytocin and Cognitive Behavioral Therapy in Drug Dependence Terminated NCT00975416 Phase 4 Intranasal Oxytocin;Placebo
24 A Randomized Controlled Trial Testing Buprenorphine as a Treatment in Opiate Dependent Pain Patients Terminated NCT00552578 Phase 4 buprenorphine/naloxone;buprenorphine/naloxone
25 Dopamine Beta-hydroxylase Inhibition Induced Blunting of Dopaminergic Response to Psychostimulant Administration. A PET Exploration of the Mechanism of Action of a New Therapeutic Strategy in Cocaine Addicts Withdrawn NCT02134002 Phase 4 Disulfiram;Placebo
26 A Randomized Controlled Trial Comparing Buprenorphine/Naloxone With Naltrexone for Treatment in Opioid Dependent Adolescents and Young Adults Withdrawn NCT01015066 Phase 4 Buprenorphine/naloxone;Naltrexone
27 AN OPEN-LABEL TRIAL OF REDUCED- DOSE PYLERA (BISMUTH, METRONIDAZOLE, TETRACYCLINE), AMOXICILLIN, AND ESOMEPRAZOLE IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION Withdrawn NCT02045251 Phase 4 Pylera based reduced regimen
28 Comparing Acute and Continuous Drug Abuse Treatment: A Randomized Clinical Trial Unknown status NCT01003496 Phase 3
29 A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial) Unknown status NCT01801397 Phase 3 osteoanabolic therapy
30 An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and Amphetamine-type Stimulant Dependence Unknown status NCT02541513 Phase 3 paliparidone
31 Effectiveness of Adjuvant Radiotherapy in Patients With Oropharyngeal and Floor of Mouth Squamous Cell Carcinoma and Concomitant Histological Verification of Singular Ipsilateral Cervical Lymph Node Metastasis (pN1-state) Unknown status NCT00964977 Phase 3
32 Cocaine/Crack Dependence: A Study of the Possible Reduction of Compulsion Under the Use of Biperiden Completed NCT01251393 Phase 3 Biperiden;Placebo
33 Job Seekers Training for Patients With Drug Dependence Completed NCT00102362 Phase 3
34 The Role of Sleep in the Treatment of Cannabis Use Disorders Completed NCT01685073 Phase 2, Phase 3 Zolpidem extended-release
35 Treating the Partners of Drug Using Pregnant Women: Stage II Completed NCT00496990 Phase 2, Phase 3
36 Linkage of Alcohol Abusers to Primary Care Completed NCT00278447 Phase 3
37 SEDATIVE PREMEDICATION: EFFICACY ON PATIENT EXPERIENCE Completed NCT01901003 Phase 3 Lorazepam;Placebo (microcrystalline celluloses)
38 Recovery Housing For Drug Dependent Pregnant Women Completed NCT00497302 Phase 2, Phase 3
39 Extended Tobacco Dependence Intervention in Buprenorphine Treatment Completed NCT01350011 Phase 3
40 BOSCOT: A Randomised Control Trial of Cognitive Behavioural Therapy Plus Treatment as Usual Versus Treatment as Usual in the Treatment of Borderline Personality Disorder Completed NCT00538135 Phase 3
41 Evaluation of Nile Tilapia (Oreochromis Niloticus) Skin as an Occlusive Biological Dressing in the Treatment of Burn Wounds: Phase III Randomized Controlled Trial Completed NCT04202289 Phase 3 Silver Sulfadiazine Cream 1%
42 The Prevention of Post Operative Cognitive Dysfunction by Ketamine: a Prospective Multicenter Randomized Blinded Placebo-controlled Trial in Elderly Patients Undergoing Elective Orthopaedic Surgery Completed NCT02892916 Phase 3 Ketamine;Placebo
43 Preventing Drug Use in Low Income Clinic Populations Completed NCT01942876 Phase 2, Phase 3
44 Reinforcing Effects of Intravenous Buprenorphine Versus Buprenorphine/Naloxone in Buprenorphine-maintained Intravenous Drug Users (P05207) Completed NCT00710385 Phase 3 Heroin;Naloxone;Low Bup Dose;High Bup Dose;Low Bup/Nal Dose;High Bup/Nal Dose;Placebo (PCB)
45 Effect of Mesalazine on Low Grade Mucosal Inflammation in Irritable Bowel Syndrome. A Pilot Double Blind Placebo Controlled Study. Completed NCT00774007 Phase 2, Phase 3 mesalazine;placebo
46 The Influence of Age on Bispectral Index Associated With Propofol-induced Sedation Completed NCT02046720 Phase 3 Propofol induced sedation
47 A Multicenter, Double-blind, Randomized, Placebo-controlled Study of Weight-Reduction and/or Low Sodium Diet Plus Acetazolamide vs Diet Plus Placebo in Subjects With Idiopathic Intracranial Hypertension With Mild Visual Loss Completed NCT01003639 Phase 2, Phase 3 Acetazolamide;Placebo
48 Child and Adolescent Trial for Cardiovascular Health (CATCH) Completed NCT00000467 Phase 3
49 The Impact of Concomitant Ultra Low Dose Infusion Naloxone and Therapeutic Infusion Opioid on Opioid Requirements in Pediatric ICU Patients Completed NCT00286052 Phase 3 Low Dose Naloxone
50 Effect of Intraoperative and Post-operative Opioids on Persistent Opioid Use in the Surgical Patient Recruiting NCT03367988 Phase 2, Phase 3 Opioid Anesthesia;Opioid-free Anesthesia

Search NIH Clinical Center for Polysubstance Abuse

Genetic Tests for Polysubstance Abuse

Genetic tests related to Polysubstance Abuse:

# Genetic test Affiliating Genes
1 Polysubstance Abuse, Susceptibility to 29 FAAH

Anatomical Context for Polysubstance Abuse

MalaCards organs/tissues related to Polysubstance Abuse:

40
Brain, Testes, Cortex, Liver, Prefrontal Cortex, Bone, Lung

Publications for Polysubstance Abuse

Articles related to Polysubstance Abuse:

(show top 50) (show all 308)
# Title Authors PMID Year
1
Polysubstance abuse-vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms. 56 61
11704927 2001
2
Association of a functional FAAH polymorphism with methamphetamine-induced symptoms and dependence in a Malaysian population. 56
23556448 2013
3
The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. 56
16972078 2006
4
A functional glutathione S-transferase P1 gene polymorphism is associated with methamphetamine-induced psychosis in Japanese population. 56
15729709 2005
5
A missense mutation in human fatty acid amide hydrolase associated with problem drug use. 56
12060782 2002
6
Association study of the CNR1 gene exon 3 alternative promoter region polymorphisms and substance dependence. 54 61
16741937 2006
7
Human cannabinoid receptor 1: 5' exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. 61 54
15289816 2004
8
Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a family-based haplotype relative risk study. 61 54
11054766 2000
9
Prolonged P300 latency in a neuropsychiatric population with the D2 dopamine receptor A1 allele. 61 54
7704037 1994
10
Substance abuse vulnerability and D2 receptor genes. 54 61
7681236 1993
11
Candida auris and endogenous panophthalmitis: clinical and histopathological features. 61
32462100 2020
12
Case Report: A Polymicrobial Vision-Threatening Eye Infection Associated with Polysubstance Abuse. 61
32431277 2020
13
Metastatic Lung Cancer Masquerading as Endophthalmitis. 61
32236164 2020
14
171 Buprenorphine - A Treatment for Psychic Pain and Suicidal Ideation? 61
32331017 2020
15
Effects of Cocaine Exposure on Astrocytic Glutamate Transporters and Relapse-Like Ethanol-Drinking Behavior in Male Alcohol-Preferring Rats. 61
32099993 2020
16
Cocaine, polysubstance abuse, and oral health outcomes, NHANES 2009 to 2014. 61
31919844 2020
17
Substance abuse effects on urinary tract: methamphetamine and ketamine. 61
31796640 2019
18
Cocaine as a rare cause of locked-in syndrome: a case report. 61
31739807 2019
19
Abnormal Presentation of Hypoxic Ischemic Encephalopathy Attributed to Polysubstance Exposure. 61
31747388 2019
20
Locomotor sensitization in male Sprague-Dawley rats following repeated concurrent treatment with 4-methylmethcathinone and 3,4-methylenedioxymethamphetamine. 61
31268871 2019
21
Gluteal compartment syndrome following alcohol intoxication: Case report and literature review. 61
31360451 2019
22
Impact of psychosocial comorbidities on clinical outcomes after liver transplantation: Stratification of a high-risk population. 61
31528246 2019
23
Commentary on "A Call for Caution in Prescribing Gabapentin to Individuals with Concurrent Polysubstance Abuse: A Case Report". 61
31291213 2019
24
A Call for Caution in Prescribing Gabapentin to Individuals With Concurrent Polysubstance Abuse: A Case Report. 61
31291212 2019
25
Marijuana Use in Pregnancy: A Review. 61
31343707 2019
26
Microsurgical Clip Reconstruction of Ruptured Dissecting PICA Aneurysm: 2-Dimensional Operative Video. 61
30872198 2019
27
Retrospective Review of Need for Delayed Naloxone or Oxygen in Emergency Department Patients Receiving Naloxone for Heroin Reversal. 61
30961922 2019
28
Therapeutic challenges for concurrent ethanol and nicotine consumption: naltrexone and varenicline fail to alter simultaneous ethanol and nicotine intake by female alcohol-preferring (P) rats. 61
30758525 2019
29
Undifferentiated Shock and Extreme Elevation of Procalcitonin Related to Kratom Use. 61
31160844 2019
30
A Fatality Involving Furanylfentanyl and MMMP, with Presumptive Identification of Three MMMP Metabolites in Urine. 61
30566582 2019
31
Decompression Hemicraniectomy for Refractory Intracranial Hypertension in Reversible Cerebral Vasoconstriction Syndrome. 61
31001036 2019
32
Osteopathic Physical Exam Findings in Chronic Hepatitis C: A Case Study. 61
30937237 2019
33
Effect of Bile Duct Ligation-induced Liver Dysfunction on Methamphetamine Pharmacokinetics and Locomotor Activity in Rats. 61
31329536 2019
34
Ephenidine, diphenidine, and methoxphenidine complications reported to the French Addictovigilance Network. 61
29956843 2018
35
Snow and Reindeer: Large Tricuspid Valve Mobile Vegetation. 61
30504520 2018
36
Hydrops and fetal hypoplastic left heart: An unexpected improvement after cessation of maternal polysubstance abuse. 61
30194993 2018
37
Exploring the association between initial serum alcohol concentration and polysubstance use: More than a simple "gateway drug" effect? 61
30662866 2018
38
Patterns and sociodemographic characteristics of substance abuse in Al Qassim, Saudi Arabia: a retrospective study at a psychiatric rehabilitation center. 61
30284986 2018
39
Dislocation rate increases with bariatric surgery before total hip arthroplasty. 61
29756506 2018
40
Acute Liver Injury Induced by Synthetic Cannabinoid Abuse. 61
30416907 2018
41
Dexmedetomidine-induced fever and delirium: A case report. 61
29574851 2018
42
Acute progressive paraplegia in heroin-associated myelopathy. 61
29483006 2018
43
Bradycardia and Syncope in a Patient Presenting With Loperamide Abuse. 61
30013863 2018
44
Nicotine as a discriminative stimulus for ethanol use. 61
29179044 2018
45
Cave diving for a diagnosis: Disseminated histoplasmosis in the immunocompromised. 61
29942759 2018
46
Unexplained Portal Gas in a Patient with an Esophageal Ulcer. 61
30643653 2018
47
Prevalence of Polysubstance Abuse and Dual Diagnosis in Patients Admitted to Alcohol Rehabilitation Units for Alcohol-Related Problems in Italy: Changes in 15 Years. 61
29016981 2017
48
Thrombotic thrombocytopenic purpura possibly triggered by Graves' disease. 61
29744115 2017
49
Possible Reversible Cerebral Vasoconstriction Syndrome Associated with Eucalyptus: Case Report. 61
29163745 2017
50
Autopsy-proven Mirtazapine Withdrawal-induced Mania/Hypomania Associated with Sudden Death. 61
29472753 2017

Variations for Polysubstance Abuse

Expression for Polysubstance Abuse

Search GEO for disease gene expression data for Polysubstance Abuse.

Pathways for Polysubstance Abuse

GO Terms for Polysubstance Abuse

Cellular components related to Polysubstance Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.43 DRD2 COMT CNR1
2 synaptic vesicle membrane GO:0030672 9.4 DRD3 DRD2
3 endocytic vesicle GO:0030139 9.37 DRD3 DRD2
4 glutamatergic synapse GO:0098978 9.33 DRD3 DRD2 CNR1
5 integral component of presynaptic membrane GO:0099056 9.32 DRD2 CNR1
6 dopaminergic synapse GO:0098691 8.96 DRD3 DRD2
7 GABA-ergic synapse GO:0098982 8.8 DRD3 DRD2 CNR1

Biological processes related to Polysubstance Abuse according to GeneCards Suite gene sharing:

(show all 45)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.83 DRD3 DRD2 COMT
2 response to toxic substance GO:0009636 9.7 DRD3 DRD2
3 response to ethanol GO:0045471 9.7 DRD3 DRD2 CNR1
4 regulation of lipid metabolic process GO:0019216 9.69 DRD3 CNR1
5 locomotory behavior GO:0007626 9.69 DRD3 DRD2
6 learning GO:0007612 9.69 DRD3 COMT
7 learning or memory GO:0007611 9.68 DRD3 CNR1
8 circadian regulation of gene expression GO:0032922 9.68 DRD3 DRD2
9 negative regulation of protein kinase B signaling GO:0051898 9.68 DRD3 DRD2
10 visual learning GO:0008542 9.68 DRD3 DRD2
11 response to nicotine GO:0035094 9.67 DRD2 CNR1
12 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.67 DRD3 DRD2
13 positive regulation of cytokinesis GO:0032467 9.67 DRD3 DRD2
14 response to amphetamine GO:0001975 9.66 DRD3 DRD2
15 regulation of dopamine secretion GO:0014059 9.66 DRD3 DRD2
16 negative regulation of protein secretion GO:0050709 9.65 DRD3 DRD2
17 arachidonic acid secretion GO:0050482 9.65 DRD3 DRD2
18 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.65 DRD3 DRD2 CNR1
19 negative regulation of adenylate cyclase activity GO:0007194 9.64 DRD3 DRD2
20 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.64 DRD3 DRD2
21 dopamine receptor signaling pathway GO:0007212 9.63 DRD3 DRD2
22 behavioral response to cocaine GO:0048148 9.63 DRD3 DRD2
23 synaptic transmission, dopaminergic GO:0001963 9.62 DRD3 DRD2
24 negative regulation of cytosolic calcium ion concentration GO:0051481 9.62 DRD3 DRD2
25 negative regulation of voltage-gated calcium channel activity GO:1901386 9.61 DRD3 DRD2
26 prepulse inhibition GO:0060134 9.61 DRD3 DRD2
27 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.6 DRD3 DRD2
28 behavioral response to ethanol GO:0048149 9.59 DRD3 DRD2
29 regulation of synaptic transmission, GABAergic GO:0032228 9.58 DRD2 CNR1
30 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.58 DRD3 DRD2
31 positive regulation of renal sodium excretion GO:0035815 9.57 DRD3 DRD2
32 G protein-coupled receptor internalization GO:0002031 9.56 DRD3 DRD2
33 regulation of potassium ion transport GO:0043266 9.55 DRD3 DRD2
34 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.54 DRD3 DRD2
35 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.51 DRD3 DRD2
36 regulation of neurotransmitter uptake GO:0051580 9.49 DRD3 DRD2
37 negative regulation of dopamine receptor signaling pathway GO:0060160 9.46 DRD3 DRD2
38 negative regulation of dopamine secretion GO:0033602 9.43 DRD2 CNR1
39 response to cocaine GO:0042220 9.43 DRD3 DRD2 CNR1
40 regulation of locomotion involved in locomotory behavior GO:0090325 9.4 DRD3 DRD2
41 acid secretion GO:0046717 9.37 DRD3 DRD2
42 response to morphine GO:0043278 9.33 DRD3 DRD2 CNR1
43 response to histamine GO:0034776 9.32 DRD3 DRD2
44 negative regulation of blood pressure GO:0045776 9.13 DRD3 DRD2 CNR1
45 dopamine metabolic process GO:0042417 8.8 DRD3 DRD2 COMT

Molecular functions related to Polysubstance Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 adrenergic receptor activity GO:0004935 9.32 DRD3 DRD2
2 dopamine binding GO:0035240 9.26 DRD3 DRD2
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.16 DRD3 DRD2
4 dopamine neurotransmitter receptor activity GO:0004952 8.96 DRD3 DRD2
5 drug binding GO:0008144 8.8 DRD3 DRD2 CNR1

Sources for Polysubstance Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....